A new study — unique in its size, scope and collaborative nature — has identified genetic variants that are associated with progression of Parkinson disease (PD). However, limitations of the study highlight the need for large-scale, phenotype-harmonized, multi-ethnic, longitudinal studies to characterize PD subtypes and develop individualized therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047 (1997).
Brockmann, K. et al. GBA-associated PD presents with nonmotor characteristics. Neurology 77, 276–280 (2011).
Brockmann, K. et al. GBA-associated Parkinson’s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. 30, 407–411 (2015).
Winder-Rhodes, S. E. et al. Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain 136, 392–399 (2013).
Marras, C. et al. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson’s disease. Mov. Disord. 31, 1192–1202 (2016).
Saunders-Pullman, R. et al. Progression in the LRRK2-asssociated Parkinson disease population. JAMA Neurol. 75, 312–319 (2018).
Iwaki, H. et al. Genetic risk of Parkinson disease and progression: an analysis of 13 longitudinal cohorts. Neurol. Genet. 5, e348 (2019).
Ryan, E., Seehra, G., Sharma, P. & Sidransky, E. GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr. Opin. Neurol. 32, 589–596 (2019).
Lerche, S. et al. Aiming for study comparability in Parkinson’s disease: proposal for a modular set of biomarker assessments to be used in longitudinal studies. Front. Aging Neurosci. 8, 121 (2016).
Lo, R. Y. et al. Clinical features in early Parkinson disease and survival. Arch. Neurol. 66, 1353–1358 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kuhlenbäumer, G., Berg, D. Parkinson disease genetics: too early to predict progression?. Nat Rev Neurol 15, 625–626 (2019). https://doi.org/10.1038/s41582-019-0264-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0264-3
